Although we showed that CRISPR deletion of Phd2 had marked effects on Fgf23 expressional control in response to mimicked hypoxia and anemia, we did not directly investigate the consequences of Phd1 or Phd3 deletion in vitro. The gene discussed is EGLN2; the disease is anemia.